HCPLive Network

Review Shows All Approved Drugs Similarly Prevent Migraines

THURSDAY, April 25 (HealthDay News) -- There is no significant difference in effectiveness in approved drugs for preventing episodic migraine frequency by 50 percent or more, according to a review published in the April issue of the Journal of General Internal Medicine.

Tatyana A. Shamliyan, MD, from the University of Minnesota, in Minneapolis, and colleagues conducted a literature review to identify randomized controlled trials (RCTs) of preventive drugs versus placebo or active treatments examining rates of ≥50 percent reduction in monthly migraine frequency or improvement in quality of life.

Based on 215 published RCTs, the researchers found that placebo was outperformed by all approved drugs, including topiramate (nine RCTs), divalproex (three RCTs), timolol (three RCTs), and propranolol (four RCTs); off-label beta blockers metoprolol (four RCTs), atenolol (one RCT), nadolol (one RCT), and acebutolol (one RCT); angiotensin-converting enzyme inhibitors captopril (one RCT) and lisinopril (one RCT); and angiotensin II receptor blocker candesartan (one RCT), in reducing monthly migraine frequency by 50 percent or more in 200 to 400 patients per 1,000 treated. Topiramate, off-label antiepileptics, and antidepressants had higher levels of adverse events, leading to treatment discontinuation. While there were no statistically significant differences in benefits between approved drugs, off-label angiotensin-inhibiting drugs and beta-blockers were the most effective and tolerable for episodic migraine prevention.

"Evidence is lacking for long-term effects of drug treatments (i.e., trials of more than three months duration), especially for quality of life," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Why do some allergic reactions produce only relatively mild symptoms while others trigger anaphylaxis and eventual death?
Obesity in children is a very complex problem. How children eat and what they believe about food and obesity is largely determined in their family units.
Kidney donors may have lower 1,25-dihydroxyvitamin D and phosphate levels. Their parathyroid hormone levels may be elevated, but with minimal effect on calcium levels.
More Reading